← United States · Coverage record
US · SEC FORM 4
Kymera Therapeutics, Inc.
KYMR · Nasdaq · CIK 0001815442 · Healthcare · Biotechnology
INSIDER SIGNAL
No active buy signal
0 qualifying P purchase groups
in the current 180-day scoring window
200 Form 4 transaction lines observed in the same window
183 sales · 17 option, withholding, award, gift or other lines
Last qualifying purchase2025-12-11 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP · $172.5M
WHY NO ACTIVE SIGNAL?
Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
AprMayJunJulAugSepOct
Booth BruceDirector
○▼▼▼▼▼▼▼▼▼▼▼▼
Mainolfi NelloChief Executive Officer
○▼○▼○▼○▼
Goodman NoahChief Business Officer
○▼○▼▼
Jacobs Bruce N.Chief Financial Officer
○○○▼
Chadwick Jeremy GChief Operating Officer
▼▼▼
Ridloff ElenaDirector
○▼
● Purchase▼ Sale○ Other
Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
No recorded active-signal snapshot
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-12-11 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP.
Recent Form 4 activity
2Purchases
275Sales
48Other Form 4 lines
53SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING183 sale line(s) · context only
OTHER17 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 9,910,014
- Previous report
- 10,530,809
- Avg daily volume
- 828,028
- Days to cover
- 12.0
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-11 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | Purchase (P) | Common Stock | 2,005,813 | USD 86.00 | USD 172,499,918 | SEC filing ↗ |
| 2025-06-30 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 317,167 | USD 44.00 | USD 13,955,348 | SEC filing ↗ |
| 2025-06-30 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | Purchase (P) | Common Stock | 655,500 | USD 44.00 | USD 28,842,000 | SEC filing ↗ |
| 2024-08-20 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | Purchase (P) | Common Stock | 1 | USD 46.41 | USD 46 | SEC filing ↗ |
| 2023-11-03 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 197,699 | USD 14.07 | USD 2,781,625 | SEC filing ↗ |
| 2023-11-02 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 216,406 | USD 11.64 | USD 2,518,966 | SEC filing ↗ |
| 2023-01-12 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 18,897 | USD 31.24 | USD 590,342 | SEC filing ↗ |
| 2023-01-11 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 22,110 | USD 29.89 | USD 660,868 | SEC filing ↗ |
| 2022-08-22 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 545,525 | USD 26.00 | USD 14,183,650 | SEC filing ↗ |
| 2022-05-27 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 65,369 | USD 14.78 | USD 966,154 | SEC filing ↗ |
| 2022-05-26 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 224,057 | USD 14.21 | USD 3,183,850 | SEC filing ↗ |
| 2022-05-20 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 10,100 | USD 14.00 | USD 141,400 | SEC filing ↗ |
| 2022-05-06 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 100,000 | USD 19.26 | USD 1,926,000 | SEC filing ↗ |
| 2022-05-05 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 150,000 | USD 19.60 | USD 2,940,000 | SEC filing ↗ |
| 2022-01-31 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 34,408 | USD 40.70 | USD 1,400,406 | SEC filing ↗ |
Form 4 evidence
325 transaction lines in the latest 365-day window; 750 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Mainolfi Nello | Sale (S) | Common Stock | 30,000 | USD 113.80 | USD 3,413,917 | SEC filing ↗ |
| 2026-10-01 | Mainolfi Nello | Option exercise / conversion (M) | Common Stock | 30,000 | USD 2.08 | USD 62,400 | SEC filing ↗ |
| 2026-09-04 | Adams Brian | Sale (S) | Common Stock | 6,371 | USD 116.83 | USD 744,297 | SEC filing ↗ |
Show recent Form 4 evidence (30 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Mainolfi Nello | Sale (S) | Common Stock | 30,000 | USD 113.80 | USD 3,413,917 | SEC filing ↗ |
| 2026-10-01 | Mainolfi Nello | Option exercise / conversion (M) | Common Stock | 30,000 | USD 2.08 | USD 62,400 | SEC filing ↗ |
| 2026-09-04 | Adams Brian | Sale (S) | Common Stock | 6,371 | USD 116.83 | USD 744,297 | SEC filing ↗ |
| 2026-07-27 | Rooney Terence | Award / grant (A) | Common Stock | 38,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-07-07 | Mainolfi Nello | Sale (S) | Common Stock | 50,000 | USD 119.00 | USD 5,950,000 | SEC filing ↗ |
| 2026-07-07 | Mainolfi Nello | Option exercise / conversion (M) | Common Stock | 50,000 | USD 2.08 | USD 104,000 | SEC filing ↗ |
| 2026-07-01 | Mainolfi Nello | Sale (S) | Common Stock | 80,000 | USD 115.30 | USD 9,223,733 | SEC filing ↗ |
| 2026-07-01 | Mainolfi Nello | Option exercise / conversion (M) | Common Stock | 80,000 | USD 2.08 | USD 166,400 | SEC filing ↗ |
| 2026-07-01 | Goodman Noah | Sale (S) | Common Stock | 3,389 | USD 114.29 | USD 387,329 | SEC filing ↗ |
| 2026-06-30 | Jacobs Bruce N. | Sale (S) | Common Stock | 77,109 | USD 114.97 | USD 8,864,858 | SEC filing ↗ |
| 2026-06-30 | Jacobs Bruce N. | Option exercise / conversion (M) | Common Stock | 61,378 | USD 5.33 | USD 327,145 | SEC filing ↗ |
| 2026-06-29 | Booth Bruce | Sale (S) | Common Stock | 76,650 | USD 108.05 | USD 8,281,905 | SEC filing ↗ |
| 2026-06-29 | Booth Bruce | Sale (S) | Common Stock | 31,283 | USD 109.48 | USD 3,424,800 | SEC filing ↗ |
| 2026-06-29 | Booth Bruce | Sale (S) | Common Stock | 45,367 | USD 107.06 | USD 4,857,104 | SEC filing ↗ |
| 2026-06-26 | Booth Bruce | Sale (S) | Common Stock | 467,878 | USD 110.29 | USD 51,603,032 | SEC filing ↗ |
| 2026-06-26 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Sale (S) | Common Stock, $0.0001 par value | 1,630,658 | USD 106.50 | USD 173,665,077 | SEC filing ↗ |
| 2026-06-25 | Goodman Noah | Sale (S) | Common Stock | 5,000 | USD 114.00 | USD 570,000 | SEC filing ↗ |
| 2026-06-25 | Goodman Noah | Option exercise / conversion (M) | Common Stock | 5,000 | USD 21.05 | USD 105,250 | SEC filing ↗ |
| 2026-06-25 | Booth Bruce | Sale (S) | Common Stock | 285,684 | USD 121.86 | USD 34,812,909 | SEC filing ↗ |
| 2026-06-25 | Booth Bruce | Sale (S) | Common Stock | 262,637 | USD 115.39 | USD 30,306,107 | SEC filing ↗ |
| 2026-06-24 | Booth Bruce | Sale (S) | Common Stock | 134,720 | USD 100.51 | USD 13,540,476 | SEC filing ↗ |
| 2026-06-23 | Booth Bruce | Sale (S) | Common Stock | 1,408 | USD 99.98 | USD 140,772 | SEC filing ↗ |
| 2026-06-22 | Goodman Noah | Sale (S) | Common Stock | 2,500 | USD 99.00 | USD 247,500 | SEC filing ↗ |
| 2026-06-22 | Goodman Noah | Option exercise / conversion (M) | Common Stock | 2,500 | USD 21.05 | USD 52,625 | SEC filing ↗ |
| 2026-06-22 | Booth Bruce | Sale (S) | Common Stock | 31,798 | USD 103.75 | USD 3,299,037 | SEC filing ↗ |
| 2026-06-22 | Booth Bruce | Sale (S) | Common Stock | 246,330 | USD 98.52 | USD 24,268,861 | SEC filing ↗ |
| 2026-06-18 | Booth Bruce | Sale (S) | Common Stock | 115,056 | USD 91.01 | USD 10,471,661 | SEC filing ↗ |
| 2026-06-17 | Booth Bruce | Sale (S) | Common Stock | 116,812 | USD 90.34 | USD 10,552,772 | SEC filing ↗ |
| 2026-06-17 | Booth Bruce | Option exercise / conversion (M) | Common Stock | 11,741 | USD 20.00 | USD 234,820 | SEC filing ↗ |
| 2026-06-02 | Jacobs Bruce N. | Option exercise / conversion (M) | Common Stock | 12,653 | USD 2.08 | USD 26,318 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | KYMR |
| CIK | 0001815442 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 750 transaction lines from 2020-08-21 to 2026-10-01 45 P purchase lines · 528 S sale lines · 177 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.